Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology (Internal Medicine) Physician in Santa Fe, NM
NPI: 1033302625Primary Practice Location
Nexus Health
2085 A S Pacheco St, Santa Fe, NM
Primary Employer
Nexus Health
nexushealth-nm.com
HQ Phone
Get M.D. Fei's Phone Numberphone_androidMobile
Get M.D. Fei's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
MA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 180 | 441 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 142 | 178 |
| 3 | 96413Infusion of chemotherapy into a vein up to 1 hour | 48 | 150 |
| 4 | 99215Established patient office or other outpatient, visit typically 40 minutes | 47 | 77 |
| 5 | 99205New patient office or other outpatient visit, typically 60 minutes | 40 | 40 |
Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer.
Authors: Zuo, Tao, Liu, Ta-Ming, Lan, Xun, Weng, Yu-I, Shen, Rulong, Gu, Fei, Huang, Yi-Wen, Liyanarachchi, Sandya, Deatherage, Daniel E, Hsu, Pei-Yin, Taslim, Cenny, Ramaswamy, Bhuvaneswari, Shapiro, Charles L, Lin, Huey-Jen L, Cheng, Alfred S L, Jin, Victor X, Huang, Tim H-M
Journal: Cancer Res
Publication Date: 2011-01-07
Modeling Human TBX5 Haploinsufficiency Predicts Regulatory Networks for Congenital Heart Disease.
Authors: Irfan Kathiriya
Publication Date: 2020-05-12
Authors: Gu, Fei, Wu, Hao
Journal: Psychometrika
Publication Date: 2016-06-30
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Osimertinib, DRUG: Ramucirumab, DRUG: Erlotinib, DRUG: Gefitinib
